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Abstract
Background: There is little data on the safety of combining radiation therapy and human immunodeficiency virus
(HIV) protease inhibitors to treat cancers in HIV-positive patients. We describe acute toxicities observed in a series
of HIV-positive patients receiving modern radiation treatments, and compare patients receiving HIV protease
inhibitors (PI) with patients not receiving HIV PIs.
Methods: By reviewing the clinical records beginning January 1, 2009 from the radiation oncology department, we
identified 29 HIV-positive patients who received radiation therapy to 34 body sites. Baseline information, treatment
regimen, and toxicities were documented by review of medical records: patient age, histology and source of the
primary tumor, HIV medication regimen, pre-radiation CD4 count, systemic chemotherapy, radiation therapy dose
and fractionation, irradiated body region, toxicities, and duration of follow-up. Patients were grouped according to
whether they received concurrent HIV PIs and compared using Pearson’s chi-square test.
Results: At baseline, the patients in the two groups were similar with the exception of HIV medication regimens,
CD4 count and presence of AIDS-defining malignancy. Patients taking concurrent PIs were more likely to be taking
other HIV medications (p = 0.001) and have CD4 count >500 (p = 0.006). Patients taking PIs were borderline less
likely to have an AIDS-defining malignancy (p = 0.06). After radiation treatment, 100 acute toxicities were observed
and were equally common in both groups (64 [median 3 per patient, IQR 1-7] with PIs; 36 [median 3 per patient,
IQR 2-3] without PIs). The observed toxicities were also equally severe in the two groups (Grades I, II, III respectively:
30, 30, 4 with PIs; 23, 13, 0 without PIs: p = 0.38). There were two cases that were stopped early, one in each
group; these were not attributable to toxicity.
Conclusions: In this study of recent radiotherapy in HIV-positive patients taking second generation PIs, no
difference in toxicities was observed in patients taking PIs compared to patients not taking PIs during radiation
therapy. This suggests that it is safe to use unmodified doses of PIs and radiation therapy in HIV cancer patients,
and that it is feasible to use PIs as a radiosensitizer in cancer therapy, as has been suggested by pre-clinical results.
Background
HIV and malignancies
Historically, HIV infection is associated with a much
higher risk of specific cancers [1-4]. In particular, diag-
nosis of Kaposi sarcoma, non-Hodgkin lymphoma
(NHL), or cervical cancer are considered acquired
immunodeficiency syndrome (AIDS)-defining malignan-
cies [5]. However, increasing effectiveness of anti-retro-
viral therapy (ART) has led to decreased mortality in
Europe and North America from opportunistic infec-
tions and AIDS-defining malignancies [5-8], while mor-
tality from non-AIDS-defining and non-HIV-associated
cancers has been increasing [8,9].
Response to cancer therapy is also different in the
HIV patient population. Initial reports found increased
radiotoxicity in HIV patients receiving treatment for
Kaposi sarcoma, cervical carcinoma, while there was no
difference in adverse effects of radiation therapy for
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ciency [12], DNA repair deficiency, or cell cycle dysre-
gulation may increase radiosensitivity [13-15]. However,
radiation therapy remains a cornerstone of therapy in a
number of cancers such as anal cancer [16], prostate
[17], breast [18-20], and cervical cancer [16,21].
Protease inhibitors in the treatment of HIV
P I sa r ea n t i - v i r a ld r u g st h a ti n h i b i tp r o t e a s e s ,v i r a l
enzymes which cleave polyprotein precursors into
mature viral proteins [22]. PIs are one class of anti-virals
that is used as the ‘base’ in combination with two ‘back-
bone’ drugs for treatment of HIV, antiretroviral therapy
(ART). There are currently ten PIs available; in chrono-
logical order of FDA approval, saquinavir, ritonavir,
indinavir, nelfinavir, lopinavir, atazanavir, fosamprenavir
(pro-drug of amprenavir, which is no longer available),
tipranavir, and darunavir.
Although PIs act by inhibiting HIV aspartyl protease,
they also have off-target effects. The entire class is asso-
ciated with dysregulation of glucose and lipid metabo-
lism due to homology between HIV-1 protease and
various human proteins [23-26]. In addition, some PIs
inhibit the phosphatidyl-inositol 3-kinase (PI3K)-Akt
pathway, which is shared by numerous cell homeostasis
pathways [27,28].
Non-target effects of protease inhibitors
A number of PIs have been associated with anti-cancer
activity [29]. Through PI3K-Akt and closely related
pathways, PIs induce apoptosis of tumor cells [30-36].
Although PIs have been shown to directly effect tumor
cell death, use of PIs has not reduced cancer risk in
HIV patients, suggesting that PIs would not be clinically
effective anti-cancer monotherapies [37]. Although inef-
fective alone, PIs synergize with other cancer therapies
such as radiotherapy [38].
Initial studies suggested that nelfinavir upregulates
vascular endothelial growth factor (VEGF) and downre-
gulates hypoxia-inducible factor 1 alpha (HIF-1a).
Although VEGF can increase tumor oxygenation, the
HIF1-a hypoxia factor can mediate radiation resistance
[39,40]. However, HIF-1a knockdown studies suggest
that radiosensitivity induced by PIs is independent of
HIF-1a [28,40-42]. In a number of cancers, resistance to
radiotherapy is mediated by the PI3K-Akt pathway, sug-
gesting an alternative mechanism of PI-induced radio-
sensitization [43-45]. Preclinical studies with nelfinavir
in head-and-neck cancer [46] and non-small cell lung
cancer [28] cell lines found downregulation of Akt to be
associated with increased sensitivity to radiation.
Although PI-induced radiosensitization of cancers was
shown to be independent of HIF-1a, PIs have been
shown to induce systemic vascular stress [47]. Preclinical
in vivo studies suggest that in addition to direct effect on
the tumor cells, PIs may inhibit PI3K-Akt activation in
tumor vasculature, suppressing hypoxia pathways and
leading to reduced radiation resistance [48,49]. Other
clinical reports also suggest that PIs and radiotherapy
interact on tumor vasculature similar to the effects of
radiation and bevacizumab, an anti-angiogenic antibody
[50].
Protease inhibitors and radiotherapy
A retrospective review (14 patients receiving PIs and 28
controls) did not find severe toxicities attributable to
combination of PIs and radiotherapy for cancer in HIV+
patients [11,51-54]. There are ten prospective trials, nine
of which are on-going (a phase II trial was terminated
due to poor enrollment): five phase I studies, and four
studies that have a phase II component. One published
phase I trial in pancreatic cancer showed the following
toxicites one of which was life-threatening: severe nau-
sea and vomiting and increase in liver enzymes and
bilirubin due to stent occlusion [55]. Given the incon-
clusive safety data on combining PIs and radiation ther-
apy to treat cancer in HIV patients, we reviewed a series
of HIV patients receiving radiation therapy for
malignancies.
Methods
Patient identification
In accordance with a research protocol approved by the
Institutional Review Board, patients were identified by
review of clinical records from January 1, 2009-October
31, 2010 in the Department of Radiation Oncology at
The Johns Hopkins Hospital. Patients were included if
they had documented HIV infection and received radia-
tion therapy at Johns Hopkins.
Retrospective review
Medical records for included patients were reviewed for
HIV medications, cancer diagnosis and stage, radiation
therapy (site, dose, fractionation, completion or early
stopping), age at time of radiation therapy, cancer che-
motherapy, acute (< 6 weeks after end of radiation ther-
apy) toxicities categorized by Common Toxicity Criteria
for Adverse Events version 3.0 (CTCAE) grade. All
patients receiving radiation therapy were evaluated at
least once per week for treatment toxicity, and side
effects were recorded prospectively in an electronic
record system.
Statistical analysis
Patients were categorized by type of malignancy (AIDS-
defining, HIV-associated, non-HIV associated), taking
non-PI HIV medications (yes/no), and by baseline CD4
count (< 50, <200, <500, 500). Toxicities were categorized
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analyzed using Pearson’s chi-square test with JMP 8.0
(SAS Institute Inc.). Statistical significance was defined as
aP e a r s o n ’s chi-square p-value < 0.05.
Results
We retrospectively reviewed acute toxicities in a series
of patients with a history of HIV infection and receiving
radiation therapy; in this series, we compared patients
who received concurrent PIs with patients who did not
receive concurrent PIs. Eighteen patients received con-
current PIs and radiation therapy; one patient received
radiation therapy for two different malignancies, and
one patient received radiation for three recurrences of
NHL. There were eleven patients with a history of HIV
infection but not treated with PIs who received radiation
therapy; one patient received three regimens of radiation
therapy, twice for brain metastasis and once for testicu-
lar metastasis.
Patient characteristics
Characteristics of patients receiving concurrent protease
inhibitor are presented in Table 1 while characteristics
of patients not receiving concurrent protease inhibitor
are presented in Table 2. There were 34 total courses of
radiation treatment delivered (21 with PIs, 13 without
PIs) for a variety of histologies, including HIV-defining
(0 with PIs; 3 [23%] without PIs), HIV-associated (11
[58%] with PIs; 5 [38%] without PIs), non-HIV-asso-
ciated malignancies (8 [42%] with PIs, 5 [38%] without
PIs), and non-malignancies (keloid scar and dural arter-
iovenous fistula with PIs, none without PIs). The median
age was 50 (interquartile range [IQR] 47-56). The differ-
ence between the two groups in number of AIDS-
Table 1 Baseline data: patients receiving concurrent protease inhibitor
# Cancer diagnosis Age Concurrent systemic
therapy
Baseline
CD4
Non-PI HIV regimen PI
1a Ductal carcinoma, breast T2N1M0 47 None 104 lamivudine, raltegravir RTV, DRV
1b SCC, anus T3N0M0 49 5-FU, mitomycin C 68 lamivudine, raltegravir RTV, DRV
2 SCC, vulva T1bN1b, stage IIIa 26 cisplatin 1647 emtricitabine, tenofovir RTV, ATZ
3 Ductal carcinoma, breast T1cN0M0, stage I 47 None 474 emtricitabine, tenofovir,
raltegravir
RTV, ATZ
4 SCC, anus T2N0M0, stage II 47 None NR emtricitabine, tenofovir,
raltegravir
RTV, DRV
5 Adenocarcinoma, prostate cT2bNXM0, GS 3+3, PSA
8.7, stage II
58 None WNL efavirenz, emtricitabine,
tenofovir
RTV, LPV
6 Adenocarcinoma, prostate cT1cNXM0, GS 3+4, PSA
4.9, stage II
73 androgen deprivation 1105 raltegravir RTV, DRV
7 Adenocarcinoma, prostate cT1cNXM0, GS 4+3, PSA
5.1stage II
69 androgen deprivation 536 abacavir, lamivudine RTV, ATZ
8 Renal cell carcinoma, lateral chest wall, metastatic,
stage IV
50 sutent 766 emtricitabine, tenofovir,
efavirenz
RTV, ATZ
9 Arteriovenous fistula, dura mater 57 None 944 abacavir, lamivudine, raltegravir RTV, LPV
10 SCC, tonsil T2N2bM0 53 cisplatin 956 emtricitabine, tenofovir RTV, LPV
11 Primary CNS lymphoma, CNS 44 None 4 None RTV, DRV
doxil, cytoxan,
12 NHL, neck and axilla, stage IV 53 vincristine, prednisone 57 abacavir, lamivudine RTV
13a NHL, pelvis, stage IV 53 None 120 abacavir, lamivudine RTV, ATZ
13b NHL, axilla, stage IV 55 None 39 abacavir, lamivudine RTV, LPV
13c NHL, temple, stage IV 56 None 87 abacavir, lamivudine RTV, LPV
14 Primary CNS lymphoma, CNS 21 None 0 emtricitabine, tenofovir RTV, DRV
15 Ductal carcinoma, breast T2N0M0, stage IIa 58 None NR emtricitabine, tenofovir RTV, LPV
16 SCC, anus T1N0M0, stage I 43 5-FU, mitomycin C 547 abacavir, lamivudine RTV, LPV
17 Primary CNS lymphoma, CNS 23 None 10 emtricitabine, tenofovir RTV, DRV
18 Keloid scar, posterior scalp 47 None WNL zidovudine 300 mg,
lamivudine 150 mg
NFV
Patients are uniquely identified by numbers, repeated treatments on a patient are distinguished by a letter after the number.
NHL = non-Hodgkin lymphoma.
cT = clinical tumor, pT = pathological tumor, GS = Gleason score, PSA = prostate specific antigen.
RTV = ritonavir, DRV = darunavir, ATZ = atazanavir, LPV = lopinavir, NFV = nelfinavir.
WNL = Reported as within normal limits, NR = not reported.
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cance (p = 0.06), but the remainder of the malignancies
(HIV-associated and non-HIV-associated) are not differ-
ently distributed in the two groups (p = 0.9). 29 cases
had documented pre-treatment CD4 counts; 4 were <50
(4 [24%] with PIs), 13 were <200 (9 [53%] with PIs, 4
[33%] without PIs), and 21 were <500 (10 [59%] with
PIs; 11[92%] without PIs). Patients taking PIs were more
likely than patients not taking PIs to have a CD4
count≥500 (7 [41%] with PIs; 1 [8%] without PIs; p-
0.006).
Radiation treatment
For the 29 patients receiving radiation therapy, 15
patients were treated with definitive or adjuvant dose
regimens (9 receiving PIs, 6 without PIs), while 14
patients received palliative radiation doses (9 receiving
PIs, 5 without PIs). The exact definition of definitive/
adjuvant versus palliative dose varied based on body
site. Definitive/adjuvant dose was at least 5400 cGy for
brain (conventional fractionation equivalent), 7000 cGy
for head and neck, 5400 cGy for breast, 4500 cGy for
pelvis, and 7800 cGy for prostate. Palliative doses also
varied based on body site and disease histology, but
were lower than definitive/adjuvant dose regimens.
HIV medications and systemic chemotherapy
Systemic chemotherapy regimens for these two groups
of patients are presented (Table 1 and 2). Of the 32
treatments for cancer (19 with PIs, 13 without PIs), 13
included systemic chemotherapy regimens (7 [37%] with
PIs; 6 [46%] without PIs). 21 of the 29 patients were
receiving HIV medications (17 [94%] with PIs; 4 [36%]
without PIs; p = 0.001).
In the group receiving PIs, the most common PI was
ritonavir (20 [95%]), followed by darunavir and lopinavir
(7 [33%] each), atazanavir (5 [24%]), and only one [5%]
patient received nelfinavir (Table 1 and 2).
Toxicities
Follow-up and observed toxicities are presented in Table
3 and 4. The median follow-up of all patients was 18
weeks [IQR 8-30], but the follow-up for patients not
taking PIs (median 13 weeks [IQR 5-18]) was much
shorter than the follow-up for patients taking PIs (med-
ian 21 weeks [IQR 10-38]). The limited follow-up in the
group not taking PIs prevented comparison of long-
term toxicities.
There were 64 acute toxicities in the group receiving
PIs (30 grade 1, 30 grade 2, 4 grade 3). In the group not
receiving PIs, there were 36 acute toxicities (23 grade 1,
1 3g r a d e2 ) .T h em e d i a nn u m ber of toxicities experi-
enced per patient was not different between the groups
(3 [IQR 1-7] with PIs; 3 [IQR 2-3] without PIs). Chi-
square analysis of the distribution of severity did not
find statistically significant difference in the severity of
toxicities between the two groups (p = 0.38). One radia-
tion treatment in each group was stopped early, but
neither of these was secondary to toxicity (no grade 3
toxicities in either patient).
Table 2 Baseline data: patients not receiving concurrent protease inhibitor
# Cancer diagnosis Age Concurrent
systemic therapy
Baseline
CD4
Non-PI HIV regimen
1 SCC, cervix T4N1M0, stage IVa 29 cisplatin 189 None
2 SCC, cervix, stage IIb 34 cisplatin 189 None
3 Cholangiocarcinoma, abdomen pT3N1M0 53 xeloda 300 efavirenz, emtricitabine, tenofovir
4 Adenocarcinoma, prostate TXNXM1, stage IV 48 None 399 None
5 Meningioma, CNS 46 None 408 None
6 Adenocarcinoma, prostate cT1cNXM0, GS 62 androgen 1047 None
3+4, PSA 20.6, stage II deprivation
7 NSCLC, brain met, stage IV 57 None NR None
8a DLBCL, brain met, stage IV 46 None 214 efavirenz, emtricitabine, tenofovir
8b DLBCL, brain met recurrence, stage IV 46 None 214 efavirenz, emtricitabine, tenofovir
8c DLBCL, testicular met, stage IV 46 None 214 efavirenz, emtricitabine, tenofovir
9 Adenocarcinoma, prostate cT2aNXM0, GS 61 None 150 efavirenz, emtricitabine, tenofovir
3+4, PSA 1.1, stage II
10 SCC, cervix, stage IIIb 57 cisplatin 116 None
11 SCC, anal 49 mitomycin C and
xeloda
450 efavirenz, emtricitabine, tenofovir
Patients are uniquely identified by numbers, repeated treatments on a patient are distinguished by a letter after the number.
NHL = non-Hodgkin lymphoma, DLBCL = diffuse large B-cell lymphoma.
cT = clinical tumor, pT = pathological tumor, GS = Gleason score, PSA = prostate specific antigen.
NR = not reported.
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Our retrospective review of HIV-positive patients receiv-
ing radiation therapy found no increased toxicity in
patients receiving concurrent PIs. The number and
severity of toxicities experienced per patient were not
found to be different in patients who were concurrently
taking PIs compared to those who were not. There were
differences in the baseline characteristics and medication
regimens of the two groups. First, there were no cases of
AIDS-defining malignancies in the group treated with
PIs. This difference coincided with a difference in all
HIV treatment and CD4 count. Significantly more
patients in the non-PI group did not receive any medi-
cation to manage HIV, and significantly more patients
in the non-PI group had CD4 counts below 500. This
difference may reflect the efficacy of PIs and ART in
controlling HIV, and a resulting decrease in opportunis-
tic malignancies that has been observed with progressive
generations of ART[9]. Although ART is typically
initiated if the CD4 count is below 500, there are a
number of other factors that contribute to the decision
to initiate therapy, such as patient preference, adherence
to prescriptions, and HIV strain. There was no associa-
tion between CD4 count and adverse events.
There have been a number of case reports and small
case series documenting seve re toxicities in HIV
patients receiving radiation therapy. A meta-analysis of
case reports and case series found severe toxicities in
HIV patients receiving radiation therapy for Kaposi sar-
coma and cervical carcinoma, but not in other malig-
nancies [10]. Our results are in accordance with the
only published study evaluating toxicities from interac-
tion between PIs and radiation therapy [11]. Plastaras et
al. reviewed 14 patients with concurrent PIs and 28
patients in the absence of PI, and found no difference in
toxicity from radiation therapy. Although this group
Table 3 Radiation regimen, follow-up and toxicities in patients receiving concurrent protease inhibitor
# F/U
[weeks]
Region treated Dose
(fractionation)
[cgy]
Complete RT
regimen
Acute toxicity and CTC grade
1a 75 right breast 5800 (200) yes dermatitis 2, pruritis 1, hyperpigmentation 2, fatigue 1, pain 1
1b 0 pelvis 3600 (180) no, prescribed
5400
fatigue 2, pain 2, nocturia 2, anorexia 1, proctitis 2
fatigue 1, pain 1, nocturia and urinary
2 9 pelvis and left vulva 4500 (180) yes frequency 1, dysuria 2, proctitis 1, diarrhea
1, mucosal drainage 1
3 36 right breast 5130 (270) yes fatigue 2, pain 3, dermatitis 1, hyperpigmentation 2
4 18 pelvis and anus 3000 (200) yes dysuria 1
5 82 prostate and SV 6720 (320) yes dysuria and nocturia and urinary frequency 2, anorexia 1, diarrhea 1,
hematochezia 1
6 18 prostate and SV 8000 (200) yes nocturia and urinary frequency 2
7 7 prostate and SV 7800 (200) yes pain 1, dysuria and urinary frequency and incontinence 2,
constipation 1, diarrhea 1
8 8 left lateral chest wall 3600 (300) yes dermatitis 1
9 38 brain 2000 (2000) yes none
10 25 head and neck 7000 (200) yes dermatitis 3, fatigue 3, dysphonia 1, xerostomia 2
11 21 brain 3000 (300) yes fatigue 2, pain 2, nausea 2, insomnia 2, anorexia 2, vomiting 2, ataxia 2
12 23 right neck and left axilla 3000 (200) yes fatigue 1, pain 1, dermatitis 1, dysgeusia 1, dysphonia 1, xerostomia 1
13a 147 right pelvis 3000 (250) yes fatigue 1
13b 13 right axilla and ulcerating
skin lesion
3060 (180) yes dermatitis 2, drainage 3, pruritus 1
13c 7 right temple and
subcutaneous skin lesion
3060 (180) yes dermatitis 2
14 19 brain 3000 (300) yes fatigue 1
15 86 right breast 6000 (200) yes dermatitis 1
fatigue 1, pain 2, nausea 1, nocturia and
16 85 pelvis 5040 (180) yes urinary frequency 1, anorexia 2, proctitis 1,
diarrhea 2, dermatitis 2
17 10 brain 3000 (300) yes altered mental status in intensive care throughout treatment
18 31 posterior scalp 1600 (400) yes none
Patients are uniquely identified by numbers, repeated treatments on a patient are distinguished by a letter after the number.
F/U = follow-up.
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patient series was treated between 1993-2007 for the
control group and 1997-2006 for the PI group. Inclusion
of patients from this time period may have been
reflected in the distribution of PIs and the distribution
of malignancies treated. Nearly all patients in the Plas-
taras et al. study were treated with nelfinavir, three were
treated with saquinavir (the oldest available PI), and one
was treated with amprenavir (no longer available). 29
(69%) of 42 malignancies were AIDS-defining or
strongly associated with HIV. These results may be lim-
ited by the baseline characteristics: AIDS-defining and
HIV-associated malignancies are more heavily repre-
sented than in the current HIV+ population and PI regi-
mens are evolving rapidly. Although not related to the
years from which the patients were sampled, only 6 of
the 14 patients from the PI group had documented CD4
count: one was <50, two were <200, and three <500. No
association was observed between CD4 count and radia-
tion toxicity, but the data is limited.
Our study characterizes the safety of radiation therapy
combined with the newer generation of PIs in treatment
of non-AIDS defining malignancies which are increasingly
common in the era of improved ART. The series
included only patients treated from January 1, 2009
onwards: of the 18 patients receiving PIs, 16 (89%) were
receiving a dual-PI regimen; only two were taking a
mono-PI regimen (one ritonavir and one nelfinavir). The
case series included more malignancies not associated
with HIV or AIDS (ductal carcinoma of the breast, renal
cell carcinoma, cholangiocarcinoma, and meningioma),
and two non-malignancies (dural AVM, and keloid scar)
that were treated with radiation. Half of the patients in
this case series received definitive or adjuvant radiation
dose regimens (45-78 Gy). These patients were distribu-
ted equally in the group with PIs and in the group with-
out PIs, and combination of definitive/adjuvant doses of
radiation with PIs did not increase toxicities over defini-
tive/adjuvant radiation doses alone. The present study
more than doubles the reported number of patients trea-
ted with HIV PIs and radiation from 14 to 32.
The limitations of this study include the small size,
short follow-up, heterogeneous nature of our cohort,
and the differences between the control group and the
PI treatment group. As discussed before, in addition to
not taking PI, the control group also received less non-
PI HIV medications and had a lower median CD4
count. The factors that underlie these two differences
may confound the results. In addition, although we col-
lected data on late toxicities, there was insufficient fol-
low-up (21 weeks [IQR 10-38] with PIs, 13 [IQR 5-18]
without PIs) to assess differences in late toxicities.
Extended follow-up is necessary to determine the impact
on long term toxicities. In addition, the majority of the
cases received ritonavir combined with a second PI.
Ritonavir does not inhibit Akt, which is a proposed
Table 4 Radiation regimen, follow-up and toxicities in patients not receiving concurrent protease inhibitor
# F/U
[weeks]
Region treated Dose (fractionation) [cgy] Complete RT
regimen
Acute toxicity and CTC grade
1 6 Pelvis 5400 (180) yes fatigue 1, nocturia 1, proctitis 2, gastrointestinal bleed
3, dermatitis 2
2 6 vaginal cuff
brachytherapy
4500 and 2500 HDR (180 and
500 HDR)
yes
3 18 Abdomen 5040 (180) yes fatigue 1, anorexia 1, nausea 1
4 13 thoracic spine 3000 (300) yes fatigue 1
5 29 Brain 5400 (180) yes pain 2, edema 2
6 44 prostate and SV 7800 (200) yes nocturia and urinary frequency and urgency 2, urinary
retention 1
7 20 Brain 5300 (250 and 18 Gy gamma-
knife boost)
yes memory impairment 1, concentration impairment 1
8a 0 prostate and SV 7800 (200) yes dysuria and nocturia 2, urinary retention 1,
constipation 1
8b 13 Pelvis 3780 and 1400 HDR (180 and
700 HDR)
no fatigue 2, anorexia 1, dermatitis 2
8c 4 Pelvis 3000 and 1200 IORT (200 and
1200 HDR)
yes fatigue 1, pain 1, nocturia 1, anorexia 1, proctitis 1,
diarrhea 1
9 13 Brain 2400 (200) yes fatigue 2, pain 2,
10 5 brain (repeated) 2400 (200) yes fatigue 2, anorexia 1, constipation 1, dermatitis 1,
11 0 Testicles 2700 (180) no, prescribed
4140
pain 1, constipation 1, dermatitis 1
Patients are uniquely identified by numbers, repeated treatments on a patient are distinguished by a letter after the number.
F/U = follow-up.
HDR = high dose radiation.
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there are no published studies evaluating the radiosensi-
tizing effect of darunavir, atazanavir, or lopinavir, which
were used in combination with ritonavir by the majority
of the patients. Prior studies on radiosensitization by PIs
have not found a defining structural characteristic which
would predict whether a PI will increase radiosensitivity.
In spite of these limitations, this retrospective review
provides valuable information about the acute toxicity of
combining radiation with current PI therapies. Review
of this contemporary series of patients did not find an
increase in acute toxicity from the combination of the
newest generation of HIV PIs and radiation therapy to
treat diverse pathologies.
Conclusions
Preclinical data has suggested that PIs used in the treat-
ment of HIV may radiosensitize cancer cells, but case
reports have suggested that PIs may exacerbate radio-
toxicity in normal tissue. Review of a set of HIV-positive
radiation therapy patients did not reveal increased toxi-
city in patients taking PIs during radiation therapy. Our
cohort doubles the number of patients in the current lit-
erature on the acute safety profile of combining PIs and
radiation therapy. These data suggest that clinical trials
of PIs as radiosensitizers will not encounter increased
acute toxicity.
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